Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $54.75

Shares of Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) have been given an average rating of "Buy" by the six analysts that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have covered the stock in the last year is $54.75.

A number of analysts recently weighed in on SLN shares. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Morgan Stanley reissued an "overweight" rating and set a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Wednesday, January 29th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of Silence Therapeutics in a report on Monday, December 2nd.

Silence Therapeutics Price Performance

SLN traded up $0.44 during trading on Friday, hitting $6.05. The company had a trading volume of 333,318 shares, compared to its average volume of 312,353. The company has a market cap of $181.08 million, a PE ratio of -3.85 and a beta of 1.05. The business has a 50-day moving average of $6.52 and a 200-day moving average of $13.52. Silence Therapeutics has a 1-year low of $4.82 and a 1-year high of $27.72.

Hedge Funds Weigh In On Silence Therapeutics

A number of large investors have recently added to or reduced their stakes in SLN. Millennium Management LLC lifted its position in Silence Therapeutics by 91.2% during the second quarter. Millennium Management LLC now owns 782,941 shares of the company's stock worth $14,876,000 after acquiring an additional 373,523 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Silence Therapeutics during the third quarter worth $56,000. The Manufacturers Life Insurance Company bought a new stake in shares of Silence Therapeutics during the third quarter worth $318,000. Verition Fund Management LLC acquired a new position in shares of Silence Therapeutics during the third quarter worth $207,000. Finally, Eventide Asset Management LLC acquired a new position in Silence Therapeutics in the third quarter valued at $11,635,000. Institutional investors own 98.73% of the company's stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.